Literature DB >> 10080844

Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

J Lagergren1, R Bergström, A Lindgren, O Nyrén.   

Abstract

BACKGROUND: The causes of adenocarcinomas of the esophagus and gastric cardia are poorly understood. We conducted an epidemiologic investigation of the possible association between gastroesophageal reflux and these tumors.
METHODS: We performed a nationwide, population-based, case-control study in Sweden. Case ascertainment was rapid, and all cases were classified uniformly. Information on the subjects' history of gastroesophageal reflux was collected in personal interviews. The odds ratios were calculated by logistic regression, with multivariate adjustment for potentially confounding variables.
RESULTS: Of the patients interviewed, the 189 with esophageal adenocarcinoma and the 262 with adenocarcinoma of the cardia constituted 85 percent of the 529 patients in Sweden who were eligible for the study during the period from 1995 through 1997. For comparison, we interviewed 820 control subjects from the general population and 167 patients with esophageal squamous-cell carcinoma. Among persons with recurrent symptoms of reflux, as compared with persons without such symptoms, the odds ratios were 7.7 (95 percent confidence interval, 5.3 to 11.4) for esophageal adenocarcinoma and 2.0 (95 percent confidence interval, 1.4 to 2.9) for adenocarcinoma of the cardia. The more frequent, more severe, and longer-lasting the symptoms of reflux, the greater the risk. Among persons with long-standing and severe symptoms of reflux, the odds ratios were 43.5 (95 percent confidence interval, 18.3 to 103.5) for esophageal adenocarcinoma and 4.4 (95 percent confidence interval, 1.7 to 11.0) for adenocarcinoma of the cardia. The risk of esophageal squamous-cell carcinoma was not associated with reflux (odds ratio, 1.1; 95 percent confidence interval, 0.7 to 1.9).
CONCLUSIONS: There is a strong and probably causal relation between gastroesophageal reflux and esophageal adenocarcinoma. The relation between reflux and adenocarcinoma of the gastric cardia is relatively weak.

Entities:  

Mesh:

Year:  1999        PMID: 10080844     DOI: 10.1056/NEJM199903183401101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  707 in total

Review 1.  Management of gastro-oesophageal reflux disease in general practice.

Authors:  J Dent; R Jones; P Kahrilas; N J Talley
Journal:  BMJ       Date:  2001-02-10

2.  No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

3.  Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.

Authors:  R V Lord; D Salonga; K D Danenberg; J H Peters; T R DeMeester; J M Park; J Johansson; K A Skinner; P Chandrasoma; S R DeMeester; C G Bremner; P I Tsai; P V Danenberg
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

4.  Overweight and adenocarcinoma of the oesophagus.

Authors:  R N Maric; K K Cheng
Journal:  BMJ       Date:  2001-02-10

5.  Barrett's oesophagus: the continuing conundrum.

Authors:  T J McGarrity
Journal:  BMJ       Date:  2000-11-18

Review 6.  Medical treatment of Barrett's esophagus.

Authors:  S J Spechler
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 7.  Antireflux surgery in the management of Barrett's esophagus.

Authors:  T R DeMeester
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 8.  Newer therapies for gastroesophageal reflux disease: numb, burn, or stitch?

Authors:  J Jailwala; R Shaker
Journal:  Curr Gastroenterol Rep       Date:  2001-06

9.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 10.  Endoscopic therapies for gastroesophageal reflux disease.

Authors:  George Triadafilopoulos
Journal:  Curr Gastroenterol Rep       Date:  2002-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.